Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors

Research output: Contribution to journalArticlepeer-review

Abstract

Dinutuximab is a costly life-prolonging immunotherapy for high-risk neuroblastoma. We used a large pediatric inpatient database to analyze the use of antineoplastic immunotherapy in patients with malignant adrenal tumors 1 year after Food and Drug Administration approval of dinutuximab for high-risk neuroblastoma. On multivariate modeling, children of Black race (odds ratio [OR] 0.62, P =.04; referent non-Black) and the lowest ZIP code income quartile (OR 0.74, P =.03; referent wealthier 3 quartiles) were significantly less like to receive antineoplastic immunotherapy. These results suggest substantial disparities in the distribution of a vital therapy in children with advanced cancer.

Original languageEnglish (US)
Article numbere28522
JournalPediatric Blood and Cancer
Volume67
Issue number9
DOIs
StatePublished - Sep 1 2020

Keywords

  • adrenal cancers
  • dinutuximab
  • disparities
  • epidemiology
  • immunotherapy
  • neuroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors'. Together they form a unique fingerprint.

Cite this